This approach provides an opportunity to target tumors with mutations in tumor suppressor genes such as BRCA1, BRCA2, and RAD51, where loss of function results in the tumorigenic consequences of deficient homologous recombination [24,109]. This evidence concerns the gene BRCA2 and neoplasm.